Faculty profile

Jason Matthews

ResearcherPharmacology and ToxicologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Jason Matthews

Researcher

Pharmacology and Toxicology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
28 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (3 CIHR), most recently in 2018.
Supervisor on 1 trainee award (1 CIHR), most recently in 2008.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Aryl Hydrocarbon Receptor Genomics Dioxins Gene Editing Inflammation Polycyclic Aromatic Hydrocarbons Tcdd-Inducible Poly-Adp-Ribose Polymerase Transcriptional Regulation

Latest papers

Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.
Pharmacological reviews · 2026 · senior author
Serglycin modulates inflammation and metabolism in macrophages.
iScience · 2026
Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation.
The EMBO journal · 2026

All 69 publications

Latest funding

Mono-ADP-ribosylation by TIPARP regulates AHR biology and dioxin toxicity
CIHR · 2018 · Principal investigator
$837,675
TiPARP is a mono-ADP-ribose transferase and a repressor of aryl hydrocarbon receptor activity
CIHR · 2012 · Nominated PI
$645,574
Regulation of gene expression by aryl hydrocarbon receptor and estrogen receptor alpha
CIHR · 2009 · Nominated PI
$627,805

All 5 grants and awards

69 publications.

Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.

Bobrovs R, Olafsen NE, Åhrling SS, Matthews J

Pharmacological reviews2026Senior author

DOI: 10.1016/j.pharmr.2026.100146 PMID: 42385421

Serglycin modulates inflammation and metabolism in macrophages.

Porteymour S, Sajib SD, von Hofsten S, Doncheva AI, Bjørnvall CD, Hegge B, Gautier M, Grujic M, Kolan P, Krishnan KC, Matthews J, Dalen KT, Pejler G, Kolset SO, Knutsen E, Norheim FA

iScience2026

DOI: 10.1016/j.isci.2026.115235 PMID: 41971985

Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation.

Gorelik A, Đukić N, Smith R, Chatrin C, Suyari O, Matthews J, Ahel I

The EMBO journal2026

DOI: 10.1038/s44318-025-00656-1 PMID: 41326691

PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling.

Olafsen NE, Åhrling SS, Rasmussen M, Erlingsson LAM, Granly EN, Takaoka A, Matthews J

Cellular oncology (Dordrecht, Netherlands)2025Senior author

DOI: 10.1007/s13402-025-01150-w PMID: 41432900

Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients.

Bartkeviciene A, Jasukaitiene A, Zievyte I, Ivanauskiene S, Stachneviciute G, Jenceviciute K, Karvelyte G, Stukas D, Sikarske A, Urboniene D, Maimets T, Jaudzems K, Vitkauskiene A, Matthews J, Gulbinas A, Dambrauskas Z

Frontiers in immunology2025

DOI: 10.3389/fimmu.2025.1655258 PMID: 41357201

PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice.

Xu J, Yu T, Yue Z, Lu X, Zhang Y, Wang L, Åhrling SS, Smith MR, Li YC, Matthews J, Lin H

Cell reports2025

DOI: 10.1016/j.celrep.2025.116130 PMID: 40811059

Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans.

Izzati FN, Choksi H, Giuliana P, Abd-Rabbo D, Elsaesser H, Blundell A, Affe V, Kannen V, Jame-Chenarboo Z, Schmidt EN, Kuypers M, Avila DB, Chiu ESY, Badmaev D, Cui H, Matthews J, Mallevaey T, Macauley MS, Brooks DG, Edgar LJ

Cell reports2025

DOI: 10.1016/j.celrep.2025.115933 PMID: 40608513

CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.

Gorelik A, Paulo JA, Schroeter CB, Lad M, Shurr A, Mastrokalou C, Siddiqi S, Suyari O, Brognard J, Walter D, Matthews J, Palmer TM, Gygi SP, Ahel I

Proceedings of the National Academy of Sciences of the United States of America2025

DOI: 10.1073/pnas.2424985122 PMID: 40493189

Loss of aryl hydrocarbon receptor reduces pancreatic tumor growth by increasing immune cell infiltration.

Kannen V, Olafsen NE, Das S, Giuliana P, Izzati FN, Choksi H, Åhrling SS, Cappello P, Teino I, Maimets T, Jaudzems K, Gulbinas A, Dambrauskas Z, Edgar LJ, Grant DM, Matthews J

Biochemical pharmacology2025Senior author

DOI: 10.1016/j.bcp.2025.116872 PMID: 40090596

Exposure to fine particulate matter in adults is associated with immune cell gene expression related to inflammation, the electron transport chain, and cell cycle regulation.

Rundblad A, Das S, Ginos BNR, Matthews J, Holven KB, Voortman T, Ulven SM

Environmental epigenetics2025

DOI: 10.1093/eep/dvaf008 PMID: 40510537

Something wrong or missing on this profile? Suggest a correction

Jason Matthews

Research

Latest papers

Latest funding

Aryl hydrocarbon receptor pharmacology-mechanisms, ligands, and therapeutic potential.

Serglycin modulates inflammation and metabolism in macrophages.

Ubiquitin pathway blockade reveals endogenous ADP-ribosylation marking PARP7 and AHR for degradation.

PARP7 and aryl hydrocarbon receptor differentially regulate mammary cancer cell proliferation and STING-induced type I interferon signalling.

Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients.

PARP7 inhibition stabilizes STAT1/STAT2 and relieves experimental autoimmune encephalomyelitis in mice.

Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans.

CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity.

Loss of aryl hydrocarbon receptor reduces pancreatic tumor growth by increasing immune cell infiltration.

Exposure to fine particulate matter in adults is associated with immune cell gene expression related to inflammation, the electron transport chain, and cell cycle regulation.

Mono-ADP-ribosylation by TIPARP regulates AHR biology and dioxin toxicity

TiPARP is a mono-ADP-ribose transferase and a repressor of aryl hydrocarbon receptor activity

Regulation of gene expression by aryl hydrocarbon receptor and estrogen receptor alpha

CIHR team in developmental toxicology

Investigating the cross-talk between the aryl hydrocarbon receptor and estrogen receptor alpha

Frequent collaborators

Chiara Gorrini

Shinya Ito

Thierry Mallevaey

Haissi Cui

Melanie Powis

Parameswaran Krishna Nair

Simon Rousseau

Carolyn Baglole